JP Morgan Initiates Coverage On Neumora Therapeutics with Overweight Rating, Announces Price Target of $21
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Tessa Romero initiates coverage on Neumora Therapeutics (NASDAQ:NMRA) with an Overweight rating and a price target of $21.
October 10, 2023 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan has initiated coverage on Neumora Therapeutics with an Overweight rating and a price target of $21.
The initiation of coverage by JP Morgan with an Overweight rating indicates a positive outlook for Neumora Therapeutics. The price target of $21 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100